Exegenesis Bio to Present Data on Delivery Platform, BBB-penetrating AAV Capsid and Research programs at ASGCT 29th Annual Meeting
PHILADELPHIA, PA, May 11, 2026 – Exegenesis Bio, biopharmaceutical company focused on gene therapies and oligonucleotide-based drugs with globally leading delivery vector technologies, is pleased to announce that two oral presentations and three posters will be presented at American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting, May 11-15, 2026 in Boston, MA.
Oral Presentations
Title: Transferrin receptor-targeting AAV achieved superior and broad CNS transduction in multiple
species after intravenous administration
Session: AAV capsid engineering IV
Time: 8:45 – 9:00 AM (ET), May 15, 2026
Abstract #: 425
Presenter: Zhenhua Wu, Ph.D.
Title: AAV-Mediated RNA Interference Targeting Nav1.7 Provides Durable Relief of Hyperalgesia in Preclinical Models of Chronic Pain
Session: Neurologic diseases VII
Time: 11:00 – 11:15 pm (ET), May 15, 2026
Abstract #: 487
Presenter: Chunjuan Song, Ph.D.
Poster Presentations
Title: Neutralizing antibody resistant AAV9 capsid variants generated by directed evolution
Time: 5:00– 6:30 pm (ET), May 13, 2026
Abstract #: 2024
Title: Engineered AAV capsids with enhanced muscle tropism and reduced hepatic transduction
Time: 5:00– 6:30 pm (ET), May 14, 2026
Abstract #: 3024
Title: EXG202: An AI-Engineered AAV Gene Therapy Enabling Multi-Pathway Angiogenic Suppression in Fundus Neovascular Diseases
Time: 5:00– 6:30 pm (ET), May 14, 2026
Abstract #: 3365
For further information please contact: BD@ExegenesisBio.com
Exegenesis Bio to Present Data on Next Generation BBB-penetrating AAV Capsids & Intravitreal nAMD Gene Therapy at the American Society of Gene and Cell Therapy Meeting
Exegenesis Bio Announces FDA Clearance of Investigational New Drug (IND) Application for EXG102-031: A Novel Gene Therapy for the Treatment of neovascular Age-Related Macular Degeneration (nAMD)
– Phase 1 clinical trial to be initiated in Q1 2023 – The first clinical stage gene therapy for treatment of nAMD that targets all known subtypes of VEGF and ANG2
PHILADELPHIA–(BUSINESS WIRE) — Exegenesis Bio, a rapidly growing global gene therapy company is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for EXG102-031, a recombinant adeno-associated virus (rAAV) based gene therapy that is being studied for the treatment of neovascular Age Related Macular Degeneration (nAMD), the leading cause of severe vision loss and irreversible blindness worldwide. Read full press release
Exegenesis Bio Appoints Mahen Gundecha Chief Business Officer
PHILADELPHIA, PA, September 15, 2021 (BUSINESS WIRE) – Exegenesis Bio, a rapidly growing global gene therapy company, developing innovative genetic medicines for eye, CNS and liver-directed diseases is pleased to announce the appointment of Mahen Gundecha as Chief Business Officer. Read full press release
Exegenesis Bio Opens Philadelphia and Boston Offices and Announces Expansion Plans
PHILADELPHIA, PA, Sep 8, 2021 (BUSINESS WIRE) – Exegenesis Bio, a rapidly growing global gene therapy company, developing innovative genetic medicines for eye, CNS and liver-directed diseases is pleased to announce the next phase of its business expansion, including plans to double in size during the next 12 months and opening of business offices in Philadelphia, research operations in Boston and a regional office in Singapore. Read full press release
Exegenesis Bio Completes Series B++ Financing; Raises $120 M to Date
PHILADELPHIA, PA, June 23, 2021 (BUSINESS WIRE) – Exegenesis Bio, a rapidly growing global gene therapy company, developing innovative genetic medicines for eye, CNS and liver-directed diseases is pleased to announce the completion of its series B++ financing, raising over $50 M of venture investments in this round. The round was led by Hillhouse Capital Group and included existing investors LYFE Capital and BioTrack Capital, as well as new investors Temasek Holdings, CPE and Lake Bleu Capital. Read full press release